Background: Distal-leg skin biopsies are an endorsed objective test for confirming SFPN. ENF densities ≤5th centile of the population distribution are considered diagnostic of SFPN. Most laboratories use a single threshold (e.g., 3.8 ENF/linear mm) to determine normality of ENF results. The value of factoring demographics into diagnostic thresholds is untested. Objective: To develop and test a model of normal ENF density that incorporates demographics. Materials and Methods: With IRB permission, we obtained distal-leg skin biopsies from 373 normal volunteers (8-92 years) including 42 children. PGP9.5-immunolabeled ENF were measured using standard clinical methods. Results: Young people aged 8-23 had far more ENF than older adults (426 vs. 227/mm 2 ; p b 0.001). Females had more ENF than males (314 vs. 247/mm 2 ; p b 0.001) and Asians had more than agematched Whites, Blacks, and Hispanics (336 vs. 237/mm 2 ; p b 0.001). 13 subjects ≤23 years with repeat biopsies at different ages lost 46 ENF/mm 2 on average per year, whereas older subjects (n = 9) lost 13 ENF/mm 2 per year. We developed and compared a multivariate model of ENF density incorporating age, gender, and race to the single diagnostic threshold. Had we applied the single threshold to all 105 biopsies from patients ≤40 years that our lab interpreted as having SFPN in 2012-2013 using the multivariate model, 75% would have received false negative (normal) diagnoses. Conclusions: Different models yield contradictory interpretations of the same biopsies. Incorporating demographic covariates improves diagnostic sensitivity, especially for young patients. Repeat biopsies document rapid reduction in epidermal innervation during young adulthood.
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Patients and Institutional Review Board (IRB) approval were obtained. Introduction: GNE-myopathy is an autosomal recessive myopathy with distal muscle weakness and the formation of rimmed vacuoles (RVs). Mutations in GNE result in the decrease of sialic acid that is necessary for glycosylation of MUC1. The extracellular domain of MUC1 has the highly glycosylated tandem repeat domain containing precursor of sialylated carbohydrate antigen KL-6. In this study, we examined KL-6/MUC1 in muscle, serum, and fibroblasts. Materials and methods: The muscle biopsy specimens and laboratory data of GNE-myopathy (n = 6), sporadic inclusion body myositis (sIBM; n = 12), polymyositis (PM: n = 8), and normal control (NC: n = 5) were examined. These specimens were subjected to immunohistochemistry, immunofluorescent technique, and western blot analysis. Fibroblasts from two GNE-myopathy patients cultured with or without ManNAc were also examined by western blot analysis. Results: In GNE-myopathy, inclusions and RVs were immunopositive for pTDP-43, MUC1 and KL-6, but the sarcolemma was not. On the other hand, the sarcolemma was also immunopositive for MUC1 and KL-6 in sIBM. In PM and NC, the pale immunoreactivity for MUC1 and KL-6 was observed in the sarcolemma and cytoplasm. Western blot demonstrated the decrease of MUC1 and KL-6 in the skeletal muscle of GNE-myopathy. Serum KL-6 levels of GNE myopathy patients were lower than those of other neuromuscular disease patients (p b 0.05). Fibroblasts showed the increase of MUC1-C and KL-6 according to ManNAc treatment (p b 0.03). Conclusion: This study suggests that the decrease of KL-6/MUC1 reflects the hypoglycosylation as pathogenesis of GNE-myopathy. Serum and muscular KL-6/MUC1 might be a useful biomarker for GNE-myopathy. doi:10.1016/j.jns.2015.08.1204
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